Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Cara Therapeutics reports solid Q4 earnings amidst growth opportunities

Cara Therapeutics showcased strong revenue growth and positive feedback on KORSUVA injection sales in Q4 2022.
While facing challenges such as demand instability and regulatory uncertainties, the company remains confident in its growth prospects.
Strategic investments, milestone anticipation, and financial stability position Cara well for future value creation and market expansion.

Cara Therapeutics reports strong Q1 revenue, optimistic about pipeline growth

Cara Therapeutics delivered solid revenue in Q1 2023 driven by the successful launch of KORSUVA and Kapruvia. While facing increased operating expenses, the company remains optimistic about its pipeline's potential. Strategic focus on KORSUVA's success and ongoing R&D efforts position Cara for future growth.

Cara Therapeutics reports solid Q2 earnings amidst regulatory uncertainties

Cara Therapeutics posted strong financial performance in Q2 2023, driven by robust net sales and cash reserves, with a focus on maximizing shareholder value.
The company faces challenges related to potential CMS changes and European market dynamics but sees opportunities in international expansion and regulatory engagement.
Overall, Cara Therapeutics remains optimistic about the commercial prospects of its key products and pipeline, aiming for sustained growth and market leadership.

Cara Therapeutics extends cash runway, faces funding challenges ahead

Cara Therapeutics reports strong financials with extended cash runway. Progress in late-stage programs and successful monetization of royalties. Facing challenges with funding limitations and uncertainties around data releases.

Cara Therapeutics extends cash runway to 2026 amidst revenue challenges

Cara Therapeutics strategically focused on NP and oral DSK programs to drive growth.
Strong demand for KORSUVA injection but challenges from reimbursement changes.
Confidence in NP program and potential partnerships signal future opportunities.
Financially extended runway to 2026 but facing liquidity challenges with $1.8 million cash.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cara Therapeutics: 200% Upside Possible With FDA Approval

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2021 Results - Earnings Call Transcript

Cara (CARA) delivered earnings and revenue surprises of -10.91% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q2 Loss, Misses Revenue Estimates

Shares of Cara Therapeutics (NASDAQ:CARA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 12.96% year over year to ($0.61), which missed the estimate of ($0.53).

Cara Therapeutics: Q2 Earnings Insights

– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 –

Cara Therapeutics Reports Second Quarter 2021 Financial Results

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

STAMFORD, Conn., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, August 9, 2021 at 4:30 p.m. ET to report second quarter 2021 financial results and provide a corporate update.

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive

Biogen

Ocugen, Inc.

It pays to know what could cause them to move and when.

How to Buy Biotech Stocks This Summer

The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.

Is Cara Therapeutics a Buy for Summer 2021?

Aurora Cannabis

Evogene

Greenlane Holdings

GrowGeneration Corp

HEXO Corp

Innovative Industrial Properties

Coffee Holding

Akerna Corp

Neptune Wellness Solutions Inc.

Power REIT

Village Farms International

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

12 Cannabis Stocks That Lit Up Wall Street This Week

Is Cara Therapeutics a Buy?

Applied DNA Sciences

Arena Pharmaceuticals

Canopy Growth

Corbus Pharmaceuticals Holdings

Flora Growth Corp

OrganiGram Holdings Inc.

SNDL Inc.

cbdMD Inc

Zynerba Pharmaceuticals

Here Are the Cannabis Stocks That Caught Fire This Week

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2021 Results - Earnings Call Transcript

Shares of Cara Therapeutics (NASDAQ:CARA) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 24.19% year over year to ($0.47), which beat the estimate of ($0.59).

Cara Therapeutics: Q1 Earnings Insights

– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP –

Cara Therapeutics Reports First Quarter 2021 Financial Results

STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 4:30 p.m. ET to report first quarter 2021 financial results and provide a corporate update.

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

The company reported disappointing results from a phase 2 study.

Why Cara Therapeutics Stock Is Crashing Today

The stock price of Cara Therapeutics Inc (NASDAQ: CARA) fell from $25.79 to $15.64 as of 8:38 AM ET. This is why it happened.

CARA Stock: From $25.79 To $15.64 Pre-Market Explanation

Cara Therapeutics Inc (NASDAQ: CARA) shares dive after as investors react to topline results from its KARE Phase 2 trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. The trial's primary efficacy endpoint was the change from baseline in the weekly mean of the daily 24-hour Itch score at week 12 of the treatment period.

Cara Therapeutics' Stock Plummets As Korsuva Flunks In Mid-Stage Atopic Dermatitis Study

– Study did not meet Primary Endpoint of worst-itch NRS change from baseline at        week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics: Upcoming PDUFA May See Some Upside

Aphria

Curaleaf Holdings, Inc.

GW Pharmaceuticals

AdvisorShares Pure US Cannabis ETF

Weed stocks are red hot right now due to Democratic control of Congress and the White House as well as a recent spate of state cannabis legalizations. The post The 7 Top Weed Stocks From Q1 That You Should Know About appeared first on InvestorPlace.

The 7 Top Weed Stocks From Q1 That You Should Know About

STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Healthcare Conference on Wednesday, April 14, 2021 at 2:15 p.m. ET.

Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

News for Cara Therapeutics Stock (CARA)